Q-omics provides the consensus-scored MIR507 profile across patient tissues and cancer cell-line models. MIR507 expression is associated with patient survival in 7 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, MIR507 is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, MIR507 RNA expression shows 5,966 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight SKCM, and KIRC as cancer lineages where MIR507 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR507 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR507 survival associations across molecular data types. MIR507 RNA expression shows survival associations in the most cancer types (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR507 RNA expression–survival associations across cancer types. High MIR507 expression shows unfavorable associations in SKCM, CESC, LAML, BRCA, BLCA and ESCA. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for MIR507 RNA expression.
This table summarizes MIR507 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR507. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR507 shows higher tumor expression in KIRC, KIRP and COAD. The KIRC box plot shows higher MIR507 RNA expression in tumor versus normal tissue (log2 FC = +0.232, t-test p < 0.001).
This table shows molecular features associated with MIR507 in patient tissues and cancer cell lines. In patient samples, MIR507 shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set.
